OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kasi on Findings From the CRC-MRD Consortia in CRC

December 18th 2020

Pashtoon M. Kasi, MD, MS, discusses findings from the CRC-MRD Consortia in colorectal cancer.

Dr. Bahary on the Role of Pemigatinib in Biliary Tract Cancers

December 18th 2020

Nathan Bahary, MD, PhD, discusses the role of pemigatinib in biliary tract cancers.

Dr. Rifkin on Corneal Toxicities With Belantamab Mafodotin in Multiple Myeloma

December 17th 2020

Robert M. Rifkin, MD, FACP, discusses corneal toxicities with belantamab mafodotin-blmf in multiple myeloma.

Dr. Mohyuddin on Improving Survival in Multiple Myeloma

December 17th 2020

Ghulam Rehman Mohyuddin, MD, discusses improving survival for patients with multiple myeloma.

Dr. Verstovsek on the Role of Ruxolitinib in Myelofibrosis

December 16th 2020

Srdan Verstovsek, MD, PhD, discusses the role of ruxolitinib in myelofibrosis.

Dr. Hurwitz Compares the Utility of Antiandrogens in Nonmetastatic CRPC

December 16th 2020

Michael E. Hurwitz, MD, PhD, compares the utility of antiandrogens in nonmetastatic castration-resistant prostate cancer.

Dr. Grothey on the Role of Precision Medicine in CRC

December 16th 2020

Axel Grothey, MD, discusses the role of precision medicine in colorectal cancer.

Dr. Samur on the Evolving Treatment Landscape in Multiple Myeloma

December 16th 2020

Mehmet K. Samur, PhD, discusses the evolving treatment landscape in multiple myeloma.

Dr. Price on the Rationale for Sotorasib in Advanced Gastrointestinal Cancers

December 16th 2020

Timothy Price, MBBS, DHthSc, FRACP, discusses the rationale to evaluate sotorasib in gastrointestinal cancers.

Dr. Sznol on the Challenges of Managing Immune-Related Toxicities in Melanoma

December 16th 2020

Mario Sznol, MD, discusses the challenges of managing immune-related toxicities in melanoma.

Dr. Shah on the Importance of Assessing Quality of Life in Multiple Myeloma

December 15th 2020

Nina Shah, MD, discusses the importance of assessing quality of life in multiple myeloma.

Dr. Hobbs on Managing Ponatinib-Associated Toxicities in CML

December 15th 2020

Gaby Hobbs, MD, discusses managing ponatinib-associated toxicities in chronic myeloid leukemia.

Dr. Atkins on the Benefits of Neoadjuvant Therapy in Melanoma

December 15th 2020

Michael B. Atkins, MD, discusses the benefits of neoadjuvant therapy in melanoma.

Dr. Sweet on Treatment Selection With TKIs in CML

December 15th 2020

Kendra Sweet, MD, discusses treatment selection with TKIs in chronic myeloid leukemia.

Dr. Sullivan on Treatment Options in BRAF-Mutant Melanoma

December 15th 2020

Ryan Sullivan, MD, discusses treatment options in BRAF-mutant melanoma.

Dr. Cavnar on Surgical Differences Between Right- and Left-Sided Tumors in CRC

December 15th 2020

Michael J. Cavnar, MD, discusses surgical differences between right- and left-sided tumors in colorectal cancer.

Dr. Pandalai on the Development of Peritoneal Carcinomatosis in CRC

December 15th 2020

Prakash Pandalai, MD, discusses the development of peritoneal carcinomatosis in colorectal cancer.

Dr. Pandalai on the Use of Cytoreductive Surgery Plus HIPEC in Colorectal Peritoneal Carcinomatosis

December 15th 2020

Prakash Pandalai, MD, discusses the use of cytoreductive surgery plus heated intraperitoneal chemotherapy in the treatment of patients with colorectal peritoneal carcinomatosis.

Dr. Wang on Preliminary Findings From the KOMET-001 Trial in Relapsed/Refractory AML

December 15th 2020

Eunice Wang, MD, discusses preliminary findings from the ongoing KOMET-001 trial in relapsed/refractory acute myeloid leukemia.

Dr. Powles on the Role of ctDNA Positivity in High-Risk Muscle-Invasive Urothelial Cancer

December 15th 2020

Thomas Powles, MBBS, MRCP, MD, discusses the role of circulating tumor DNA positivity in high-risk muscle-invasive urothelial cancer.